Quantitative determination of microbiom in the destination content the gut in rats
Ключові слова:
parietal microflora, microbiome, vancomycin, salmonella, bacteroidsАнотація
Introduction. The gut microbiome significantly affects the functioning of the body: it participates in the protection of the body against pathogenic microorganisms, in the processes of metabolism, inhibition of inflammatory responses, in the formation of innate and adaptive immune response in the intestinal mucosa. One of the reasons for changing the microbiota is the use of antibiotics. Therefore, the processes of interaction of antibiotics, Salmonella enteritidis and Salmonella typhimurium with representatives of normal intestinal microflora are of particular interest. Materials and methods. The quantitative and qualitative composition of the wall microbiota in rats by bacteriological method, the statistical analysis of data using the program StatSoft Statistica v12 were conducted. Results & discussion. With the introduction of vancomycin and S. enteritidis, S. typhimurium in groups II, III, IV there was a decrease in E. coli levels by 10, 7 and 110 times, respectively (p≤0.05). The number of P. aeruginosa decreased significantly only in the third group (p≤0.05). The number of representatives of Bacteroides spp. significantly decreased by several thousand times (group II) and by 70 and 87 times (groups III and IV) (p≤0.05). The content of E. faecalis and E. faecium decreased by 861,6 and several thousand times (group II, III, IV) (p≤0.05). The number of Proteus spp. significantly decreased in group II by 27 times and increased rapidly in group IV (p≤0.05). Group III showed a sharp decrease in the content of representatives of Enterobacter spp. and Klebsiella spp. in 847 and 150 times, and in group II there is an increase in their number by 7 and 46 times, respectively (p≤0.05). The quantitative composition of Peptostreptococcus anaerobius decreased significantly in all three study groups (p≤0.05). The level of Salmonella spp. increased in group II by 49 times and significant increase was observed in groups III and IV (p≤0.05). An intense increase in the number of Shigella spp. is noted in all three groups. The introduction of salmonella, against the background of vancomycin pre-treatment, causes a dramatic change in the composition of the microbiota in groups V and VI, namely: an increase in the number of E. coli 65 and 105 times, a significant increase in the level of P. aeruginosa in the fifth group, and in the sixth, 3 times. Also, in groups there is a decrease in the number of Bacteroides spp. 9 and 10 times (p≤0.05). The content of E. faecalis and E. faecium decreased significantly only in the fifth group (p≤0.05). The number of Proteus spp. decreases 17 times in group V and also a significant decrease was observed in group VI (p≤0.05). A sharp increase in the content of representatives of Enterobacter spp. and Klebsiella spp. was observed in the fifth and sixth groups (p≤0.05). However, representatives of Peptostreptococcus anaerobius in V and VI groups decreased 20 and 9 times, respectively (p≤0.05). The number of Salmonella spp. decreased only in group V 7 times (p≤0,05). There was also a decrease in the number of Shigella spp. 538 and 860 times, respectively (p≤0.05). With the introduction of experimental animals B. fragilis treated with S. enteritidis, S. typhimurium on the background of vancomycin pre-treatment, a significant decrease in the level of E. coli in group VII, and in VIII - by 538 times (p≤0.05). The number of P. aeruginosa in groups VII and VIII decreased significantly and the number of representatives of Bacteroides spp. naturally increases (p≤0.05). The content of E. faecalis and E. faecium increased by 10 and 19 times in the seventh and eighth groups respectively, and the number of Proteus spp. decreases only in Group VII 322 times (p ≤0.05). Also, in VII and VIII groups there is a sharp decrease in the content of representatives of Enterobacter spp. and Klebsiella spp. (p≤0.05). The level of representatives of Peptostreptococcus anaerobius increased significantly 7 and 12 times (groups VII and VIII, respectively) (p≤0.05). The number of S. enteritidis and S. typhimurium in the VII and VIII groups decreased intensively with less pronounced decrease in the level of Shigella spp. (p≤0.05). Conclusions. The introduction of B. fragilis can be used in the treatment of inflammatory bowel diseases or diseases with impaired barrier function of the intestine.Посилання
Macpherson NL, Harris Macpherson AJ. Interactions between commensal intestinal bacteria and the immune system. Nature Reviews Immunology. 2004. Vol. 4. P. 478–485.
Deplancke B, Gaskins Deplancke HR. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. The American Journal of Clinical Nutrition. 2001. Vol. 73. P. 1131–1141.
Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011. Vol. 474. P. 327–336.
Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiology. 2008. Vol. 16. P. 107–114.
Vollaard EJ, Clasener HA. Colonization resistance. Antimicrobial Agents and Chemotherapy. 1994. Vol. 38. P. 409–414.
Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut.Current Opinion in Microbiology. 2011. Vol. 14. P. 82–91.
Monack DM, Bouley DM, Falkow SJ. Salmonella typhimurium persists with in macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNgamma neutralization. Experimental Medicine. 2004. Vol. 199. P. 231–241.
Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010. Vol. 156. P. 3216–3223.
Ubeda C, Pamer EG. Antibiotics, microbiota and immune defense.Trends Immunology. 2012. Vol. 33. P. 459–466.
Pérez-Cobas AE, Artacho A, Knecht H, Ferrús ML, Friedrichs A, Ott SJ. Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLoS One. 2013. Vol. 8. P. 201-208.
Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K. Antibiotics in early life alter the murine colonic microbiome and adiposity.
Nature. 2012. Vol. 488. P. 621–626.
Zhang Y, Limaye PB, Renaud HJ, Klaassen CD. Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice.Toxicology and Applied Pharmacology. 2014. Vol. 277. P. 138–145.
Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Review of Anti - infective Therapy. 2010. Vol. 8. P. 435–454.
Wlodarska M, Willing B, Keeney KM, Menendez A, Bergstrom KS, Gill N. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis.
PubMed. 2011. Vol. 79. P. 1536–1545.
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability.
PubMed. 2009. Vol. 58. P. 1091–1093.
Еrtazzoni Minelli E, Benini A, Barzoi E, DeBastiani G, Periti P. Effects on intestinal microflora during systemic antimicrobial prophylaxisin orthopaedic patients: Teicoplanin versus Cefazolin. Recent Advances in Chemotherapy. 1992. Vol. 1. P. 1230-1231.
Santos RL, Raffatellu M, Bevins CL, Adams LG, Tukel C, Tsolis RM, Baumler AJ. Life in the inflamed intestine, Salmonella style.PubMed. 2009. Vol. 17. P. 498–506.
Сarroll IM, Chang YH, Park J. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathogenes. 2010. Vol. 2. Р. 19.
Parkes GC, Rayment NB, Hudspith BN. Distinct microbial population exist in the mucosal-associated microbiota of subgroups of irritable bowel syndrome. Neurogastroenterol Motil. 2012. Vol. 24. Р. 31–39.
Awoniyi M, Miller SI, Wilson CB, Hajjar AM, Smith KD. Homeostatic regulation of Salmonella-induced mucosal inflammation and injury by IL-23. PubMed. 2012. Vol. 7. P. 731-737
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER. An obesity-associated gut microbiome with increased capacity for energy harvest. PLoS One. 2006. Vol. 444. P. 1027–1031.
Sekirov I, Tam NM, Jogova M, Robertson ML, Li Y. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. PubMed. 2008. Vol. 76. P. 4726–4736.
Kerckhoffs AP, Samson M, van der Rest ME. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. PloS One. 2009. Vol. 15. Р. 2887-2892.
Panda S, Elkhader I, Casellas F, López Vivancos J, García Cors M, Santiago A. Short-term effect of antibiotics on human gut microbiota. PLoS One. 2014. Vol. 9. P. 954-967.
Penders J, Thijs C, Van den Brandt PA, Kummeling I, Snijders B. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. PubMed. 2007. Vol. 56. P. 661–667.
Stecher B, Chaffron S R. Käppeli Like Will to Like: Abundances of Closely Related Species Can Predict Susceptibility to Intestinal Colonization by Pathogenic and Commensal Bacteria.
PLoS Pathogens 2010. Vol. 6. № 1: e1000711.
Forbes J, Domselaar V. Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments With in the Gastrointestinal Tract of Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases. 2016. Vol. 22. P. 817–825.
Sekirov I, Tam NM, Jogova M, Robertson ML, Li Y. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. PubMed. 2008. Vol. 76. P. 4726–4736.
Ubeda C, Pham N, Trevor C. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. Current Opinion in Microbiology. 2014. Vol. 17. P. 67–74.
Hyun Joo Song, Ki-Nam Shim, Sung-Ae Jung. Antibiotic-Associated Diarrhea. Korean Journal Internal Medicine. 2008. Vol. 23. P. 9–15.
Monica Vera-Lise Tulstrup, Gerd Christensen E, Carvalho V. Antibiotic Treatment Affects Intestinal Permeability and Gut Microbial Composition in Wistar Rats Dependent on Antibiotic Class. PLoS ONE. 2015. Vol. 10. Р. 12.
Barthel M, Hapfelmeier S, Quintanilla-Martinez L. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host . Infections Immunology. 2003. Vol. 71. P. 2839-2858.
Taylor DN, McKenzie R, Durbin A. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clinical Infections Diseases 2006. Vol. 42. P. 1283–1288.
Miki T, Goto R, Fujimoto M, Okada N, Hardt W.D. The Bactericidal Lectin RegIIIβ Prolongs Gut Colonization and Enteropathy in the Streptomycin Mouse Model for Salmonella Diarrhea. Cell Host Microbe. 2017. vol. 10. pii: S1931-3128(16)30519-4.
Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. Clinical & Translational Immunology. 2016. vol. 22.5(4):e73.
Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009. vol. 29. Р. 1282-6.
Surana NK, Kasper DL. The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA. Immunology Review. 2012. vol. 245. Р. 13-26.
Zeng H, Chi H. Metabolic control of regulatory T cell development and function. Trends Immunology. 2015. vol. 36. Р. 3-12.
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2020 Annals of Mechnikov's Institute
Ця робота ліцензованаІз Зазначенням Авторства – Некомерційна – Без Похідних 3.0 Міжнародна.